866-997-4948(US-Canada Toll Free)

Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : Mar 2016

Category :

Cancer

No. of Pages : 166 Pages

Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2016, provides an overview of the Human papillomavirus (HPV) Associated Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer
- The report reviews pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Human papillomavirus (HPV) Associated Cancer therapeutics and enlists all their major and minor projects
- The report assesses Human papillomavirus (HPV) Associated Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Human papillomavirus (HPV) Associated Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Overview 10
Pipeline Products for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis 11
Human papillomavirus (HPV) Associated Cancer - Therapeutics under Development by Companies 12
Human papillomavirus (HPV) Associated Cancer - Therapeutics under Investigation by Universities/Institutes 14
Human papillomavirus (HPV) Associated Cancer - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Human papillomavirus (HPV) Associated Cancer - Products under Development by Companies 18
Human papillomavirus (HPV) Associated Cancer - Products under Investigation by Universities/Institutes 21
Human papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 22
3SBio Inc. 22
Admedus Ltd 23
Advaxis, Inc. 24
Antigen Express, Inc. 25
Bionor Pharma ASA 26
Cancer Research Technology Limited 27
Cancer Therapeutics CRC Pty Ltd 28
Chong Kun Dang Pharmaceutical Corp. 29
Etubics Corporation 30
EyeGene, Inc. 31
Formune S.L. 32
Genexine, Inc. 33
Genticel S.A. 34
iBio, Inc. 35
Immunovaccine, Inc. 36
Inovio Pharmaceuticals, Inc. 37
Inthera Bioscience AG 38
Karyopharm Therapeutics, Inc. 39
Kite Pharma, Inc. 40
MedImmune, LLC 41
Novartis AG 42
Onconova Therapeutics, Inc. 43
Oryx GmbH & Co. KG 44
Profectus BioSciences, Inc. 45
Selecta Biosciences, Inc. 46
Shantha Biotechnics Limited 47
Sirnaomics, Inc. 48
Theravectys SA 49
Transgene SA 50
UbiVac, LLC 51
Vaccibody AS 52
Virometix AG 53
ViroStatics, srl 54
VLPbio 55
Human papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Target 57
Assessment by Mechanism of Action 59
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 65
ABI-1968 - Drug Profile 65
AEH-10p - Drug Profile 66
alpelisib - Drug Profile 67
Antibodies to Target E6 for HPV Associated Cancer - Drug Profile 69
Antibodies to Target E7 for HPV Associated Cancer - Drug Profile 70
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 71
Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Drug Profile 72
CerviVax - Drug Profile 74
CKD-12201 - Drug Profile 75
CTX-0197195 - Drug Profile 76
CTX-0272859 - Drug Profile 77
CTX-0291736 - Drug Profile 78
DPV-001 - Drug Profile 79
DPXE-7 - Drug Profile 81
EDA-HPVE7 - Drug Profile 82
EG-HPV - Drug Profile 83
ETBX-041 - Drug Profile 84
GTL-001 - Drug Profile 85
GTL-002 - Drug Profile 87
GX-188E - Drug Profile 88
HIV and HPV associated cancer vaccine - Drug Profile 89
human papillomavirus (7-valent) vaccine - Drug Profile 90
human papillomavirus [Serotype 16] vaccine - Drug Profile 91
human papillomavirus vaccine - Drug Profile 92
human papillomavirus vaccine - Drug Profile 93
human papillomavirus vaccine - Drug Profile 94
human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile 95
INO-3106 - Drug Profile 96
INO-3112 - Drug Profile 97
Lm-LLO-ISG15 - Drug Profile 99
LN-145 - Drug Profile 101
NIT-02 - Drug Profile 103
NP-001 - Drug Profile 104
PVX-01 - Drug Profile 105
Recombinant Vector Vaccine for HPV Associated Cervical Cancer - Drug Profile 106
Recombinant Vector Vaccine to Target E7 for HPV Associated Cancer - Drug Profile 107
Recombinant Vector Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile 108
rigosertib sodium - Drug Profile 109
sdCMV-002 - Drug Profile 114
SEL-701 - Drug Profile 115
Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers - Drug Profile 116
Small Molecules for Solid Tumors and HPV Associated Cancer - Drug Profile 117
SSS-08 - Drug Profile 118
STP-909 - Drug Profile 119
STP-911 - Drug Profile 120
Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile 121
TA-CIN - Drug Profile 122
TG-4001 - Drug Profile 124
TVGV-1 - Drug Profile 126
Vacc-HPV - Drug Profile 127
Vaccine for HPV Associated Cancer - Drug Profile 128
Vaccine for HPV Associated Cancers - Drug Profile 129
Vaccine for HPV Associated Skin Cancer - Drug Profile 130
Vaccine for Human papillomavirus Associated Cervical Cancer - Drug Profile 131
VB-1016 - Drug Profile 132
verdinexor - Drug Profile 133
VGX-3100 - Drug Profile 134
Vicoryx - Drug Profile 135
VMT-2 - Drug Profile 136
Human papillomavirus (HPV) Associated Cancer - Recent Pipeline Updates 137
Human papillomavirus (HPV) Associated Cancer - Dormant Projects 156
Human papillomavirus (HPV) Associated Cancer - Product Development Milestones 158
Featured News & Press Releases 158
Appendix 161
Methodology 161
Coverage 161
Secondary Research 161
Primary Research 161
Expert Panel Validation 161
Contact Us 161
Disclaimer 162

List of Tables
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H1 2016 14
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Number of Products under Development by Companies, H1 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2016 18
Comparative Analysis by Late Stage Development, H1 2016 19
Comparative Analysis by Clinical Stage Development, H1 2016 20
Comparative Analysis by Early Stage Development, H1 2016 21
Products under Development by Companies, H1 2016 22
Products under Development by Companies, H1 2016 (Contd..1) 23
Products under Development by Companies, H1 2016 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2016 25
Human papillomavirus (HPV) Associated Cancer - Pipeline by 3SBio Inc., H1 2016 26
Human papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H1 2016 27
Human papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis, Inc., H1 2016 28
Human papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express, Inc., H1 2016 29
Human papillomavirus (HPV) Associated Cancer - Pipeline by Bionor Pharma ASA, H1 2016 30
Human papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Limited, H1 2016 31
Human papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2016 32
Human papillomavirus (HPV) Associated Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 33
Human papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corporation, H1 2016 34
Human papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene, Inc., H1 2016 35
Human papillomavirus (HPV) Associated Cancer - Pipeline by Formune S.L., H1 2016 36
Human papillomavirus (HPV) Associated Cancer - Pipeline by Genexine, Inc., H1 2016 37
Human papillomavirus (HPV) Associated Cancer - Pipeline by Genticel S.A., H1 2016 38
Human papillomavirus (HPV) Associated Cancer - Pipeline by iBio, Inc., H1 2016 39
Human papillomavirus (HPV) Associated Cancer - Pipeline by Immunovaccine, Inc., H1 2016 40
Human papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 41
Human papillomavirus (HPV) Associated Cancer - Pipeline by Inthera Bioscience AG, H1 2016 42
Human papillomavirus (HPV) Associated Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 43
Human papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma, Inc., H1 2016 44
Human papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune, LLC, H1 2016 45
Human papillomavirus (HPV) Associated Cancer - Pipeline by Novartis AG, H1 2016 46
Human papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics, Inc., H1 2016 47
Human papillomavirus (HPV) Associated Cancer - Pipeline by Oryx GmbH & Co. KG, H1 2016 48
Human papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences, Inc., H1 2016 49
Human papillomavirus (HPV) Associated Cancer - Pipeline by Selecta Biosciences, Inc., H1 2016 50
Human papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Limited, H1 2016 51
Human papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics, Inc., H1 2016 52
Human papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys SA, H1 2016 53
Human papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H1 2016 54
Human papillomavirus (HPV) Associated Cancer - Pipeline by UbiVac, LLC, H1 2016 55
Human papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H1 2016 56
Human papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H1 2016 57
Human papillomavirus (HPV) Associated Cancer - Pipeline by ViroStatics, srl, H1 2016 58
Human papillomavirus (HPV) Associated Cancer - Pipeline by VLPbio, H1 2016 59
Assessment by Monotherapy Products, H1 2016 60
Number of Products by Stage and Target, H1 2016 62
Number of Products by Stage and Mechanism of Action, H1 2016 64
Number of Products by Stage and Route of Administration, H1 2016 66
Number of Products by Stage and Molecule Type, H1 2016 68
Human papillomavirus (HPV) Associated Cancer Therapeutics - Recent Pipeline Updates, H1 2016 141
Human papillomavirus (HPV) Associated Cancer - Dormant Projects, H1 2016 160
Human papillomavirus (HPV) Associated Cancer - Dormant Projects (Contd..1), H1 2016 161

List of Figures
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer, H1 2016 14
Number of Products under Development for Human papillomavirus (HPV) Associated Cancer - Comparative Analysis, H1 2016 15
Number of Products under Development by Companies, H1 2016 16
Number of Products under Investigation by Universities/Institutes, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 20
Comparative Analysis by Early Stage Products, H1 2016 21
Assessment by Monotherapy Products, H1 2016 60
Number of Products by Top 10 Targets, H1 2016 61
Number of Products by Stage and Top 10 Targets, H1 2016 61
Number of Products by Mechanism of Actions, H1 2016 63
Number of Products by Stage and Mechanism of Actions, H1 2016 63
Number of Products by Top 10 Routes of Administration, H1 2016 65
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 65
Number of Products by Top 10 Molecule Types, H1 2016 67
Number of Products by Stage and Top 10 Molecule Types, H1 2016 67

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *